TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2696983

Group type: EXPERIMENTAL
Intervention: Nicotine (2 mg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Nicotine (informed group)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 29
Study: 1089446

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 50 mg daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 50 mg three times a week
Number of subjects: 40
Study: 30949710

Group type: EXPERIMENTAL
Intervention: Oral Δ9‐tetrahydrocannabinol (THC)
Number of subjects: 17
Study: 28929249

Group type: EXPERIMENTAL
Intervention: Photon-initiated photoacoustic streaming (PIPS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Rotary phase of retreatment
Number of subjects: 36
Study: 26508753

Group type: EXPERIMENTAL
Intervention: Mobile Stroke Unit (MSU)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard Management (SM)
Number of subjects: 26
Study: 24262217

Group type: EXPERIMENTAL
Intervention: Enhanced Syndromic Management (ESM)
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Periodic Presumptive Treatment (PPT)
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Both ESM and PPT
Number of subjects: 549
Study: 21254853

Group type: EXPERIMENTAL
Intervention: Balneotherapy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Topical corticosteroids (TCS)
Number of subjects: 104
Study: 20384182

Group type: EXPERIMENTAL
Intervention: Children with ataxia-telangiectasia syndrome (AT)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Combined group of children with AT (males and females)
Number of subjects: 46
Study: 17532774

Group type: EXPERIMENTAL
Intervention: RinsEndo-system; 5‐mL NaOCl, 50 s
Number of subjects: 45

Group type: COMPARATOR
Intervention: Flushing with a syringe; 5‐mL NaOCl, 1 min
Number of subjects: 45

Group type: COMPARATOR
Intervention: Static application of irrigant; 3 min
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: RinsEndo-system
Number of subjects: 45

Group type: COMPARATOR
Intervention: Static application/flushing with a syringe
Number of subjects: 45
Study: 15201658

Group type: EXPERIMENTAL
Intervention: CsA‐ME
Number of subjects: 495

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 495
Study: 11952508

Group type: EXPERIMENTAL
Intervention: IVAA 500 mg twice weekly for 8 weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: IVAA 500 mg/week for 8 weeks (Group 1)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No therapy (Group 2)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Initial phase IVAA treatment
Number of subjects: 36
Study: 9811084

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 1726

Group type: EXPERIMENTAL
Intervention: Twelve-Step Facilitation (TSF)
Number of subjects: 1726

Group type: COMPARATOR
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 1726
Study: 7808063

Group type: EXPERIMENTAL
Intervention: Semiquantitative food frequency questionnaire
Number of subjects: 155

Group type: COMPARATOR
Intervention: 24-hour recall
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 155
Study: 2759127

Group type: EXPERIMENTAL
Intervention: 99mTc-MDP
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: 99mTc-DPD
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Histological examination
Number of subjects: 237
Study: 266313

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy consisting of cytarabine and 6-thioguanine for two days each month
Number of subjects: 26

Group type: COMPARATOR
Intervention: No maintenance therapy
Number of subjects: 26
Study: 30247454

Group type: EXPERIMENTAL
Intervention: Broselow tape
Number of subjects: 40
Study: 31106998

Group type: COMPARATOR
Intervention: Nitrogen addition (FN)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sterilization (FS)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sterilization and nitrogen addition (FSN)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Control (F)
Number of subjects: 18
Study: 27753684

Group type: EXPERIMENTAL
Intervention: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide plus Darunavir (E/C/F/TAF + DRV)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Baseline regimen
Number of subjects: 135
Study: 25020153

Group type: EXPERIMENTAL
Intervention: Gain-framed video
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: Loss-framed video
Number of subjects: 855

Group type: COMPARATOR
Intervention: No health message
Number of subjects: 855
Study: 23389782

Group type: EXPERIMENTAL
Intervention: TRIGEN INTERTAN nail
Number of subjects: 684

Group type: COMPARATOR
Intervention: Sliding hip screw
Number of subjects: 684
Study: 21150914

Group type: EXPERIMENTAL
Intervention: Intravenous THC (1.25 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 19645039

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control
Number of subjects: 240
Study: 17917830

Group type: EXPERIMENTAL
Intervention: Pleural fluid (PF) VEGF levels
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Serum VEGF levels
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis for PF VEGF
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis for serum VEGF
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Cascade connection and parallel operation of PF and serum VEGF
Number of subjects: 113
Study: 15499961

Group type: EXPERIMENTAL
Intervention: Prediction rule based on nine independent risk factors (gender, birthweight, educational level of the father, S. pneumoniae, cerebrospinal fluid leukocyte count, delay between admission and start of antibiotics, dexamethasone use, seizures treated with anticonvulsive therapy, prolonged fever)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Cohort of children who survived bacterial meningitis
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Risk score computed using the prediction rule
Number of subjects: 182
Study: 11180763

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (neoadjuvant chemotherapy)
Number of subjects: 0
Study: 9131311

Group type: EXPERIMENTAL
Intervention: Furosemide (1.0 mg/kg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Furosemide (1.0 mg/kg/day) plus Metolazone (0.2 mg/kg/day)
Number of subjects: 12
Study: 8482455

Group type: EXPERIMENTAL
Intervention: Percutaneous drainage
Number of subjects: 33

Group type: COMPARATOR
Intervention: Albendazole (10 mg.kg‐1.day‐1 for 8 weeks)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Combination of percutaneous drainage and albendazole
Number of subjects: 33

Group type: COMPARATOR
Intervention: Albendazole alone
Number of subjects: 33
Study: 3436158

Group type: EXPERIMENTAL
Intervention: 1 g aztreonam
Number of subjects: 225

Group type: COMPARATOR
Intervention: 2.4 mega units procaine penicillin plus 1 g probenacid
Number of subjects: 225
Study: 30630797

Group type: EXPERIMENTAL
Intervention: Oxygen-driven aerosol (Group A)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Air compressor-driven aerosol (Group B)
Number of subjects: 180
Study: 25483417

Group type: EXPERIMENTAL
Intervention: Single loading dose only
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 12 h abbreviated protocol
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 24 h standard protocol
Number of subjects: 240

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 240
Study: 23143081

Group type: EXPERIMENTAL
Intervention: External coaching targeting social climate (3 post-training booster sessions)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: External coaching targeting skills and knowledge (3 post-training booster sessions)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Management directives (control condition)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Social climate coaching
Number of subjects: 231
Study: 22317882

Group type: EXPERIMENTAL
Intervention: Hyoscine N-butylbromide (1 mL, 20 mg IV)
Number of subjects: 674

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl solution)
Number of subjects: 674
Study: 20047622

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM)-based therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17207103

Group type: EXPERIMENTAL
Intervention: 12-step treatment program
Number of subjects: 887

Group type: COMPARATOR
Intervention: Cognitive-behavioral treatment program
Number of subjects: 887
Study: 16054329

Group type: EXPERIMENTAL
Intervention: Snoezelen integrated in 24-hour care
Number of subjects: 250

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 250
Study: 12823777

Group type: EXPERIMENTAL
Intervention: Purine analogs (fludarabine, 2‐chlorodeoxyadenosine, pentostatin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibodies (rituximab, alemtuzumab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combinations of antibodies with chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies and transplantation (autologous and allogeneic)
Number of subjects: 0
Study: 9929086

Group type: EXPERIMENTAL
Intervention: Structured aerobic exercise
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Moderate lifestyle activity
Number of subjects: 40
Study: 8522226

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol at a rising dose of 2 to 8 mg, totaling 16 mg over 20 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravaginal estriol 0.03 mg/day for 10 days and 0.06 mg/day for 10 days
Number of subjects: 50
Study: 1415824

Group type: EXPERIMENTAL
Intervention: 2 mg/day of alprazolam
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 6 mg/day of alprazolam
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 2 mg/day or 6 mg/day of alprazolam
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 3922207

Group type: COMPARATOR
Intervention: Sustained-release nitroglycerin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Diltiazem added to placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Diltiazem added to nitroglycerin
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combination of nitroglycerin and diltiazem
Number of subjects: 9
Study: 30458734

Group type: EXPERIMENTAL
Intervention: CEA exponential decrease group (0.9 < R2 ≤ 1.0)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Non-exponential decrease group (R2 ≤ 0.9)
Number of subjects: 146
Study: 27323444

Group type: EXPERIMENTAL
Intervention: deqi-expectation + sharp pain
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: deqi-expectation + no-sharp pain
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: no-deqi-expectation + sharp pain
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: no-deqi-expectation + no-sharp pain
Number of subjects: 87
Study: 26513939

Group type: EXPERIMENTAL
Intervention: OHE kits and 0.05% NaF mouth rinse and brushing instructions
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: OHE kits and brushing instructions
Number of subjects: 75

Group type: COMPARATOR
Intervention: Brushing instructions (Control)
Number of subjects: 75
Study: 23530575

Group type: EXPERIMENTAL
Intervention: Enclomiphene citrate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Testosterone gel
Number of subjects: 12
Study: 21378596

Group type: EXPERIMENTAL
Intervention: Nutritional support provided to less critically ill infants during the first 3 weeks of life
Number of subjects: 1366

Group type: COMPARATOR
Intervention: Nutritional support provided to more critically ill infants during the first 3 weeks of life
Number of subjects: 1366

Group type: EXPERIMENTAL
Intervention: Total daily energy intake during the first week of life
Number of subjects: 1366

Group type: EXPERIMENTAL
Intervention: Rates of necrotizing enterocolitis
Number of subjects: 1366
Study: 18503118

Group type: EXPERIMENTAL
Intervention: Color Duplex Ultrasound (CDU)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound (CEUS)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Multislice Computed Tomography (MS-CT)
Number of subjects: 43
Study: 16543739

Group type: EXPERIMENTAL
Intervention: Slow release oral morphine (SROM)
Number of subjects: 20
Study: 14651723

Group type: EXPERIMENTAL
Intervention: Fexofenadine (180 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10757573

Group type: EXPERIMENTAL
Intervention: Dopexamine (DPX) 0.5 microg kg(‐1) min(‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dopamine (DO) 2.5 microg kg(‐1) min(‐1)
Number of subjects: 20
Study: 7825540

Group type: EXPERIMENTAL
Intervention: 50 g flaxseed/d for 4 wk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Muffins containing 25 g flaxseed
Number of subjects: 0
Study: 2195577

Group type: EXPERIMENTAL
Intervention: Clonidine (oral)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (oral)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo/Wake
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Clonidine/Sleep
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Placebo/Sleep
Number of subjects: 18
Study: 121667

Group type: EXPERIMENTAL
Intervention: Radiotherapy followed by three courses of MOPP
Number of subjects: 85

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 85
Study: 31914811

Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil plus bevacizumab (TT-B)
Number of subjects: 854

Group type: COMPARATOR
Intervention: Capecitabine plus bevacizumab
Number of subjects: 854
Study: 31590689

Group type: EXPERIMENTAL
Intervention: Intervention group with fake closed camera television (CCTV) installed after training on hand hygiene.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group without fake CCTV.
Number of subjects: 48
Study: 28415176

Group type: EXPERIMENTAL
Intervention: Iterated amplitude adjusted wavelet transform
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 26293067

Group type: EXPERIMENTAL
Intervention: 4% Gelofusine (GEL group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: 6% hydroxyehylstarch 130/40 (HES group)
Number of subjects: 36
Study: 23153900

Group type: EXPERIMENTAL
Intervention: Electronic hormonal fertility monitor (EHFM)
Number of subjects: 667

Group type: COMPARATOR
Intervention: Cervical mucus monitoring (CMM)
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 667
Study: 22275916

Group type: EXPERIMENTAL
Intervention: SCA spirometry (incentive spirometry)
Number of subjects: 49

Group type: COMPARATOR
Intervention: SCA control (no spirometry)
Number of subjects: 49
Study: 19591335

Group type: EXPERIMENTAL
Intervention: 0.05% CPC mouthrinse
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control mouthrinse
Number of subjects: 48
Study: 16581482

Group type: EXPERIMENTAL
Intervention: Right Atrial Appendage (RAA) assessment
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage (LAA) assessment
Number of subjects: 92

Group type: COMPARATOR
Intervention: Comparison of RAA and LAA
Number of subjects: 92
Study: 12838861

Group type: EXPERIMENTAL
Intervention: Nasal and nasopharyngeal debridement and cleansing and tympanic membrane puncturing suction (Group I)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Myringotomy or ventilation tube insertion (Group II)
Number of subjects: 58
Study: 10872661

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: H pylori eradication therapy
Number of subjects: 0
Study: 9090684

Group type: EXPERIMENTAL
Intervention: Oral dihydroergotamine (DHE)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8487823

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate 100 mg/kg/day for up to 5 days
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate 150 mg/kg/day for up to 5 days
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (both dosages)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study: 2962623

Group type: EXPERIMENTAL
Intervention: Sufentanil 15 micrograms + bupivacaine 12.5 mg + adrenaline 12.5 micrograms
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sufentanil 7.5 micrograms + bupivacaine 12.5 mg + adrenaline 12.5 micrograms
Number of subjects: 120

Group type: COMPARATOR
Intervention: Bupivacaine 12.5 mg + adrenaline 12.5 micrograms
Number of subjects: 120
Study: 29649056

Group type: EXPERIMENTAL
Intervention: Aloe vera gel
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 27074172

Group type: EXPERIMENTAL
Intervention: Less invasive surfactant administration (beractant 4 ml/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard treatment (intubation, surfactant administration, early extubation)
Number of subjects: 30
Study: 26671345

Group type: EXPERIMENTAL
Intervention: Remedial after-school lessons focusing on literacy and numeracy, 5 to 6 days a week for 3 years.
Number of subjects: 6000
Study: 23751740

Group type: EXPERIMENTAL
Intervention: Additional graft-distal iliac artery bypass
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Anastomotic stoma stenting
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Fogarty catheter embolectomy plus local thrombolysis
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Fogarty catheter embolectomy
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Venous thrombolysis
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 46
Study: 20718927

Group type: EXPERIMENTAL
Intervention: 300IR five-grass pollen SLIT tablets
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study: 17928199

Group type: EXPERIMENTAL
Intervention: Contrast injections (5 injections per patient)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Contrast injections (11 injections per patient)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Increasing number of contrast injections
Number of subjects: 30
Study: 15962735

Group type: EXPERIMENTAL
Intervention: Topical anesthesia with RF treatment (ThermaCool TC, Thermage)
Number of subjects: 84

Group type: COMPARATOR
Intervention: No anesthesia with RF treatment
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Half face with anesthesia, half face without anesthesia
Number of subjects: 84
Study: 12826983

Group type: EXPERIMENTAL
Intervention: Clozapine combined with lithium
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10384193

Group type: EXPERIMENTAL
Intervention: Antegrade pulmonary artery flushing with alprostadil and modified Euro‐Collins solution
Number of subjects: 14

Group type: COMPARATOR
Intervention: Antegrade flushing plus additional retrograde flushing through the pulmonary veins
Number of subjects: 14
Study: 8639011

Group type: EXPERIMENTAL
Intervention: Testosterone therapy (250 mg/mo intramuscular depot injection of Sustanon)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no testosterone treatment)
Number of subjects: 15
Study: 1516509

Group type: COMPARATOR
Intervention: IDDM patients (1569)
Number of subjects: 1569

Group type: COMPARATOR
Intervention: IDDM males and older IDDM females
Number of subjects: 1569

Group type: EXPERIMENTAL
Intervention: Metabolic control (measured by HbA1c) and body weight (% of ideal body wt)
Number of subjects: 1569

Group type: COMPARATOR
Intervention: IDDM volunteers for the DCCT
Number of subjects: 1569

Group type: COMPARATOR
Intervention: Younger IDDM women
Number of subjects: 1569
Study: 6148472

Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Impedance plethysmography
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Technetium-99m-labelled-fibrinogen scintigraphy (venoscan)
Number of subjects: 50

Group type: COMPARATOR
Intervention: X-ray venography
Number of subjects: 50
Study: 30827929

Group type: EXPERIMENTAL
Intervention: Exenatide (exendin-4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 0

Group type: COMPARATOR
Intervention: FGF21 blockage
Number of subjects: 0
Study: 29510234

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BT‐A) injection (200 units) into the gastrocnemius muscle
Number of subjects: 40
Study: 26891611

Group type: EXPERIMENTAL
Intervention: Saw Palmetto (SP) at 960 mg daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 26054177

Group type: EXPERIMENTAL
Intervention: 9.5% hydrogen peroxide whitening strip
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo strip
Number of subjects: 54
Study: 22008269

Group type: EXPERIMENTAL
Intervention: Alcohol condition (0.7 g pure ethanol/kg body weight)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 116
Study: 19707575

Group type: EXPERIMENTAL
Intervention: Relative risk reduction
Number of subjects: 2978

Group type: COMPARATOR
Intervention: Absolute summary statistics
Number of subjects: 2978

Group type: COMPARATOR
Intervention: Natural frequencies
Number of subjects: 2978
Study: 17260162

Group type: EXPERIMENTAL
Intervention: Ambulant myofeedback training including ergonomic counselling (Mfb)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Ergonomic counselling alone (EC)
Number of subjects: 79
Study: 15126001

Group type: EXPERIMENTAL
Intervention: Lipo‐PGE1 (10mg in 20ml of saline, injected intravenously as a bolus once daily for 2 weeks)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Lipo‐PGE1
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study: 11669407

Group type: EXPERIMENTAL
Intervention: CHF 1035 (10 mg/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 11579701

Group type: EXPERIMENTAL
Intervention: 40 degrees angle monitor
Number of subjects: 14

Group type: COMPARATOR
Intervention: 15 degrees angle monitor
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bifocal lens users
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nonbifocal users
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 14

Group type: COMPARATOR
Intervention: Males
Number of subjects: 14